Remission of organ failure in patients with predicted severe acute pancreatitis treated by somatostation, octreotide and cyclooxygenase-2 inhibitors
Pancreatology · 2024
DOI: 10.1016/j.pan.2023.12.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pancreatology, 2024. Verfasst von Zhi-Yin Huang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Pancreatitis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chengdu Science and Technology Bureau, National Key Research and Development Program of China, Sichuan Province Science and Technology Support Program.
Abstract (Originalsprache)
BACKGROUND: /Objectives: Persistent organ failure (OF) in severe acute pancreatitis (SAP) is caused by activation of cytokine cascades, resulting in inflammatory injury. Anti-inflammation may be helpful in OF remission in early SAP. To assess the efficacy of anti-inflammatory regimens for OF prevention and remission in patients with predicted SAP and display clinical doctors' acceptance of these strategies, we conducted this retrospective study in the real world. METHODS: Clinical data of patients with predicted SAP from 2010 to 2017 were retrospectively reviewed. Cases were divided into conventional support (C), C+ somatostatin/octreotide (C + S/O), and C + S/O + Cyclooxygenase-2-inhibitors (C + S/O + COX-2-I). The occurrence of SAP, OF, changes of proportion for three strategies, length of hospital stay, meperidine injection, and cytokine levels were compared. The constituent ratios of the three schemes over eight years were evaluated. RESULTS: A total of 580 cases (C = 124, C + S/O = 290, C + S/O + COX-2-I = 166) were included. The occurrences of SAP in the C + S/O (28.3 %) and C + S/O + COX-2-I (18.1 %) groups were significantly lower than that in C group (60.5 %, P < 0.001), mainly by reducing persistent respiratory failure (P < 0.001) and renal failure (P = 0.002). C + S/O and C + S/O + COX-2-I regimens significantly decreased new onset OF and enhanced OF amelioration within 48 h when compared with C treatment (P < 0.001) in patients with OF score
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departments of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China.
- Gastric Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
- Departments of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China. Electronic address: wangruifisher@163.com.
Förderung
- Chengdu Science and Technology Bureau
- National Key Research and Development Program of China
- Sichuan Province Science and Technology Support Program
- Sichuan University
- National Natural Science Foundation of China
Zitieren
APA
Huang, Z. Y., Gong, H., Tang, C. W., Wang, M. J., & Wang, R. (2024). Remission of organ failure in patients with predicted severe acute pancreatitis treated by somatostation, octreotide and cyclooxygenase-2 inhibitors. Pancreatology. https://doi.org/10.1016/j.pan.2023.12.006
Vancouver
Huang ZY, Gong H, Tang CW, Wang MJ, Wang R. Remission of organ failure in patients with predicted severe acute pancreatitis treated by somatostation, octreotide and cyclooxygenase-2 inhibitors. Pancreatology. 2024. doi:10.1016/j.pan.2023.12.006
BibTeX
@article{Huang2024,
author = {Huang, Zhi-Yin and Gong, Hui and Tang, Cheng-Wei and Wang, Mo-Jin and Wang, Rui},
title = {Remission of organ failure in patients with predicted severe acute pancreatitis treated by somatostation, octreotide and cyclooxygenase-2 inhibitors},
journal = {Pancreatology},
year = {2024},
doi = {10.1016/j.pan.2023.12.006}
}
EUVIMED